Braftovi
FDA Grants Accelerated Approval to Braftovi for Some Patients With Metastatic Colorectal Cancer
The FDA granted accelerated approval to encorafenib (Braftovi, Array BioPharma, a subsidiary of Pfizer) with ...
DECEMBER 23, 2024
FDA Approves Braftovi With Mektovi for Metastatic NSCLC With a BRAF V600E Mutation
The FDA approved encorafenib (Braftovi, Array BioPharma, a wholly owned subsidiary of Pfizer) with binimetinib ...
NOVEMBER 6, 2023
Erbitux Approved for Use With Braftovi for BRAF V600E–Mutated mCRC
The FDA granted approval of a new indication for cetuximab (Erbitux, Lilly) in combination with encorafenib ...
OCTOBER 1, 2021
Braftovi Approved to Treat BRAF-Mutated CRC in Combination With Erbitux
The FDA approved the use of encorafenib (Braftovi, Pfizer) in combination with cetuximab (Erbitux, ImClone) in ...
APRIL 20, 2020
FDA Approves Encorafenib and Binimetinib Combo for Melanoma With BRAF Mutations
The FDA approved the use of Braftovi and Mektovi in combination for patients with unresectable or metastatic ...
JULY 2, 2018
